Journal article icon

Journal article

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol

Abstract:

Introduction The POInT study, an investigator initiated, randomised, placebo-controlled, double-blind, multicentre primary prevention trial is conducted to determine whether daily administration of oral insulin, from age 4.0 months to 7.0 months until age 36.0 months to children with elevated genetic risk for type 1 diabetes, reduces the incidence of beta-cell autoantibodies and diabetes.

Methods and analysis Infants aged 4.0 to 7.0 months from Germ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1136/bmjopen-2018-028578

Authors


Publisher:
BMJ Publishing Group Publisher's website
Journal:
BMJ Open Journal website
Volume:
9
Issue:
6
Article number:
e028578
Publication date:
2019-06-28
Acceptance date:
2019-05-21
DOI:
EISSN:
2044-6055
Pmid:
31256036
Language:
English
Pubs id:
pubs:1028278
UUID:
uuid:11fd0a0c-4bb0-4a3a-84b0-0543785eef46
Local pid:
pubs:1028278
Source identifiers:
1028278
Deposit date:
2019-07-26

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP